Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
Germany's Fresenius SE & Co. KGAA thought its $4.3bn planned acquisition of generics firm Akorn Inc. was a...








